Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ipilimumab + gemcitabine is a combination therapy investigated for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint molecule that downregulates T-cell activation. By blocking CTLA-4, ipilimumab enhances T-cell-mediated anti-tumor immune responses. Gemcitabine is a nucleoside analog chemotherapy that inhibits DNA synthesis. This specific combination was evaluated in a Phase Ib dose-escalation study (NCT01473940) led by Northwestern University to determine safety and efficacy in patients with unresectable or recurrent pancreatic cancer.
- Brand names
- YervoyGemzar
- Other names
- ipilimumab and gemcitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on ipilimumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + gemcitabine.